Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Express Scripts
Mallinckrodt
Merck

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR TELOTRISTAT ETIPRATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Telotristat Etiprate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00853047 ↗ Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed Lexicon Pharmaceuticals Phase 2 2009-03-01 The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.
NCT01104415 ↗ Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Completed Lexicon Pharmaceuticals Phase 2 2010-06-15 The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
NCT01456052 ↗ A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis Completed Lexicon Pharmaceuticals Phase 2 2012-01-30 This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and preliminary effectiveness of two blinded dose levels of telotristat etiprate (LX1606) in participants with acute, mild to moderate ulcerative colitis on 5-aminosalicylic acid/mesalamine therapy.
NCT01677910 ↗ TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed Lexicon Pharmaceuticals Phase 3 2013-01-08 The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.
NCT01932528 ↗ An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Completed Lexicon Pharmaceuticals Phase 1 2013-08-01 To evaluate the metabolism and routes and extent of elimination of telotristat etiprate and its primary metabolite LX1033.
NCT02026063 ↗ Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Completed Lexicon Pharmaceuticals Phase 3 2014-01-14 The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Telotristat Etiprate

Condition Name

Condition Name for Telotristat Etiprate
Intervention Trials
Carcinoid Syndrome 7
Drug Interactions 3
Healthy 1
Hepatic Impairment 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Telotristat Etiprate
Intervention Trials
Serotonin Syndrome 7
Malignant Carcinoid Syndrome 7
Carcinoid Tumor 5
Syndrome 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Telotristat Etiprate

Trials by Country

Trials by Country for Telotristat Etiprate
Location Trials
United States 46
Australia 11
Canada 6
United Kingdom 5
Germany 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Telotristat Etiprate
Location Trials
California 5
Texas 4
Massachusetts 4
Iowa 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Telotristat Etiprate

Clinical Trial Phase

Clinical Trial Phase for Telotristat Etiprate
Clinical Trial Phase Trials
Phase 3 3
Phase 2 4
Phase 1 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Telotristat Etiprate
Clinical Trial Phase Trials
Completed 14
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Telotristat Etiprate

Sponsor Name

Sponsor Name for Telotristat Etiprate
Sponsor Trials
Lexicon Pharmaceuticals 12
Ipsen 2
National Cancer Institute (NCI) 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Telotristat Etiprate
Sponsor Trials
Industry 14
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Dow
AstraZeneca
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.